Results 51 to 60 of about 4,026 (142)
Immunology, EarlyView.This systematic review establishes disease‐specific dysregulations of human innate lymphoid cells (ILCs), demonstrating that an ILC1/ILC3 imbalance compromises mucosal barriers in inflammatory bowel disease, while activated ILC2s drive allergic airway inflammation.
Luan F. Lückmann +7 more
wiley +1 more source
Clinical Application of Artificial Intelligence in the Management of Chronic Hepatitis B
Journal of Gastroenterology and Hepatology, EarlyView.ABSTRACT Chronic hepatitis B (CHB) burdens the healthcare system, affecting millions of individuals worldwide with a potential progression to complications such as cirrhosis and hepatocellular carcinoma (HCC). The World Health Organization launched the chronic viral hepatitis elimination plan which aimed to eliminate chronic hepatitis B virus by 2030 ...
Jimmy Che‐To Lai +7 more
wiley +1 more source
Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir [PDF]
, 2017 Entecavir requires long-term administration. Pegylated interferon (PEG-IFN) therapy leads to significant reduction of hepatitis B surface antigen (HBs Ag) levels.
Naoki Shingaki +12 more
core +1 more source
Hepatitis B in Organ Transplantation—Current Evidence and Clinical Gaps
Transplant Infectious Disease, EarlyView.ABSTRACT Over the past several decades there have been significant advances in nucleos(t)ide analogue (NA) antiviral therapy for hepatitis B virus (HBV) and global expansion of primary prevention through immunization. Despite this, HBV remains a leading cause of chronic liver disease globally, affecting over 250 million people.
Oscar A. Fernandez‐Garcia +3 more
wiley +1 more source
Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions
Journal of Viral Hepatitis, Volume 33, Issue 12, December 2026.ABSTRACT Chronic hepatitis B (CHB) infection represents a major public health challenge in the US, with substantial unmet needs related to timely diagnosis, treatment, monitoring and disease management. This narrative review explores the CHB landscape in the US, including gaps in patient care, the evolving therapeutic landscape, the clinical utility of
Chari Cohen +3 more
wiley +1 more source
Pharmacotherapy of Chronic Hepatitis B with Entecavir
, 2009 Actually three nucleotide/nucleoside analogues are used for chronic hepatitis B: lamivudine, adefovir dipivoxil, entecavir and telbivudine. Lamivudine and adefovir are advantageous for oral administration and safety, but they induce a sustained response ...
Emilio Palumbo
core +1 more source
Journal of Viral Hepatitis, Volume 33, Issue 12, December 2026.ABSTRACT Treatment indication for chronic hepatitis B (CHB) varies across clinical guidelines. This study evaluated treatment eligibility and uptake in a large Australian cohort of people with CHB. The REACH‐B study recruited people with CHB managed through a national network of healthcare services.
Behzad Hajarizadeh +28 more
wiley +1 more source
, 2016 This ongoing, randomized phase III study assesses the safety and efficacy of entecavir versus placebo in nucleos(t)ide-naive children (2 to 12 to 6 to ≤12.
Etienne Sokal +23 more
core +2 more sources
Clinical Case Reports, Volume 14, Issue 11, November 2026.ABSTRACT Severe future liver remnant (FLR) deficiency frequently renders giant hepatocellular carcinoma (HCC) unresectable. We report a 48‐year‐old man with an unresectable 23.5‐cm giant HCC (Couinaud segments 4/5/8; baseline serum alpha‐fetoprotein (AFP), 1036.65 μg/L).
Qing Ye +5 more
wiley +1 more source
, 2011 We aimed to determine the 2-year outcomes of entecavir followed by lamivudine in patients with undetectable viral load (20 IU/mL, occurring at a range of 12 to 96 weeks. Of these, four patients had HBV DNA of less than 100 IU/mL during rebound (three had
Yuen, J +17 more
core +1 more source